Elevance Health (NYSE:ELV) Releases FY 2025 Earnings Guidance

Key Points

• Elevance Health has issued its FY 2025 earnings guidance, projecting earnings per share (EPS) of $30.00, higher than the consensus estimate of $29.88.
• The company reported quarterly earnings of $8.84 per share, missing analysts' estimates of $9.30, despite a year-over-year revenue increase of 14.3% to $49.42 billion.
• Elevance Health's quarterly dividend of $1.71 will be paid to stockholders on September 25th, representing an annualized yield of 2.2% and a payout ratio of 29.11%.

Elevance Health (NYSE:ELV - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 30.000-30.000 for the period, compared to the consensus EPS estimate of 29.880. The company issued revenue guidance of -.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Wells Fargo & Company lowered their price objective on Elevance Health from $400.00 to $330.00 and set an "overweight" rating on the stock in a research note on Friday, August 15th. Leerink Partners reissued a "market perform" rating and set a $310.00 target price (down previously from $510.00) on shares of Elevance Health in a research note on Friday, July 18th. UBS Group dropped their price objective on Elevance Health from $435.00 to $425.00 and set a "buy" rating on the stock in a report on Friday. Truist Financial dropped their price objective on Elevance Health from $500.00 to $440.00 and set a "buy" rating on the stock in a report on Wednesday, July 16th. Finally, Morgan Stanley decreased their target price on Elevance Health from $428.00 to $316.00 and set an "overweight" rating for the company in a research report on Friday, July 18th. Twelve analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Elevance Health has a consensus rating of "Moderate Buy" and an average target price of $411.06.

Elevance Health Price Performance

Shares of ELV traded up $7.13 during mid-day trading on Tuesday, hitting $315.29. The company's stock had a trading volume of 1,009,828 shares, compared to its average volume of 1,970,293. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The firm has a 50-day simple moving average of $310.41 and a 200 day simple moving average of $372.67. The firm has a market capitalization of $71.00 billion, a P/E ratio of 13.41, a P/E/G ratio of 1.15 and a beta of 0.59. Elevance Health has a 1-year low of $273.71 and a 1-year high of $559.95.

Elevance Health (NYSE:ELV - Get Free Report) last posted its quarterly earnings results on Thursday, July 17th. The company reported $8.84 EPS for the quarter, missing the consensus estimate of $9.30 by ($0.46). The business had revenue of $49.42 billion during the quarter, compared to analyst estimates of $48.26 billion. Elevance Health had a net margin of 2.83% and a return on equity of 17.59%. The firm's quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the business earned $10.12 earnings per share. Analysts predict that Elevance Health will post 33.96 EPS for the current fiscal year.

Elevance Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 25th. Investors of record on Wednesday, September 10th will be paid a $1.71 dividend. This represents a $6.84 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Wednesday, September 10th. Elevance Health's dividend payout ratio (DPR) is presently 29.11%.

Insider Activity at Elevance Health

In other news, CEO Gail Boudreaux acquired 8,500 shares of the company's stock in a transaction that occurred on Friday, July 18th. The stock was purchased at an average cost of $286.94 per share, with a total value of $2,438,990.00. Following the purchase, the chief executive officer directly owned 151,020 shares of the company's stock, valued at approximately $43,333,678.80. This trade represents a 5.96% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Susan D. Devore acquired 1,200 shares of the company's stock in a transaction that occurred on Tuesday, August 19th. The stock was purchased at an average cost of $312.15 per share, with a total value of $374,580.00. Following the completion of the purchase, the director directly owned 3,502 shares in the company, valued at $1,093,149.30. This represents a 52.13% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 0.29% of the company's stock.

Institutional Investors Weigh In On Elevance Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Advisory Services Network LLC grew its position in shares of Elevance Health by 68.3% in the second quarter. Advisory Services Network LLC now owns 3,833 shares of the company's stock valued at $1,491,000 after purchasing an additional 1,556 shares during the period. State of Wyoming acquired a new position in Elevance Health in the second quarter valued at $127,000. Kestra Investment Management LLC boosted its holdings in Elevance Health by 20.8% in the second quarter. Kestra Investment Management LLC now owns 709 shares of the company's stock valued at $276,000 after acquiring an additional 122 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in Elevance Health by 4.5% in the second quarter. CANADA LIFE ASSURANCE Co now owns 288,545 shares of the company's stock valued at $112,403,000 after acquiring an additional 12,520 shares during the last quarter. Finally, MUFG Securities EMEA plc acquired a new position in Elevance Health in the second quarter valued at $260,000. Hedge funds and other institutional investors own 89.24% of the company's stock.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.